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Background: Physical activity (PA) and its relationship with all-cause mortality suggest a 
strong and consistent inverse association. This study prospectively investigated the associa-
tion between PA level and mortality among participants of the Norwegian Women and Cancer 
(NOWAC) Study.
Methods: A total of 66,136 NOWAC participants were followed-up until December 31st 2008. 
PA level and possible confounding factors were obtained through a self-administered question-
naire at enrolment. Cox proportional hazards regression was used to calculate adjusted relative 
risks (RRs) and 95% confidence intervals (CIs) for all-cause, cardiovascular disease (CVD) and 
cancer mortality and PA levels defined from 1 to 10 on a global scale.
Results: PA levels 1–4 were associated with a significantly increased risk of all-cause mor-
tality (level 1 RR = 2.35; 95% CI: 1.94–2.84, level 2 RR = 1.71; 95% CI: 1.45–2.00, level 3 
RR = 1.30; 95% CI: 1.14–1.49, level 4 RR = 1.07; 95% CI: 0.95–1.22), compared with PA 
level 5. CVD mortality risk increased in PA levels 1–3 (level 1 RR = 3.50; 95% CI: 2.41–5.10, 
level 2 RR = 1.50; 95% CI: 0.99–2.25, level 3 RR = 1.12; 95% CI: 0.79–1.60) as did cancer 
mortality risk (RR = 1.32; 95% CI: 0.96–1.81, RR = 1.48; 95% CI: 1.19–1.84, RR = 1.26; 95% 
CI: 1.06–1.50, respectively). The magnitude of the associations was consistent across strata of 
age, smoking, and body mass index. The population attributable fractions for PA levels 1–4 
were: all-cause mortality, 11.5%; CVD mortality, 11.3%; cancer mortality, 7.8%.
Conclusion: There is a significant trend of increased risk of all-cause, CVD and cancer mortal-
ity in relation to low PA levels among Norwegian women.
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Introduction
Physical activity (PA) and its relationship with mortality have been investigated in 
several studies1–9 and a strong and consistent inverse association between PA and 
all-cause mortality has been suggested. National10 and international11 public health 
recommendations for PA are based on evidence linking a physically active lifestyle to 
reduced mortality. One review on PA and all-cause mortality concluded that there is an 
inverse dose-response relationship between total amount of PA and all-cause   mortality12 
and another review suggested that physically active men and women have a 34% lower 
premature mortality risk.2 In a study of Norwegian and Swedish women below the 
age of 60 years, PA at baseline substantially reduced all-cause mortality.13 It has not 
been convincingly documented whether this is also applicable to specific causes of 
death such as cardiovascular disease (CVD) and cancer, and the degree to which PA 
independently contributes to mortality risk has not been explored thoroughly.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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The aim of the present study was therefore to investigate 
what impact PA level has on all-cause mortality in middle-
aged women, to specify the relative risk (RR) of death due 
to CVD and cancer, and to calculate the population attribut-
able fraction (PAF) of all-cause, CVD and cancer mortality 
among women in Norway.
Methods
study population
The Norwegian Women and Cancer (NOWAC) Study is a 
population-based prospective cohort study which enrolled 
the first participants in 1991. A more detailed description of 
the cohort and design of the NOWAC Study has previously 
been described,14 as has external validity.15 Briefly, from 
1991–1997 a random sample of women aged 30–70 years 
was drawn from the National Population Register in Norway 
and invited to participate in the study. All women received a 
letter of invitation requesting informed consent and a com-
prehensive eight-page self-administered questionnaire. Of 
those invited, 102,540 women (57%) completed and returned 
the questionnaire.14 Due to study logistics, the first enrolment 
was divided into 24 mailings over 7 years. For the present 
analysis, we collected baseline information from the women 
who answered the first mailing in 1996–1997 (37,899 women), 
and those who answered a second mailing in 1998 (46,965 
women), for a total of 84,864 women. We excluded 53 women 
with a reported date of emigration or death that was before 
the date of recruitment. We excluded 8137 women with miss-
ing information on PA level at cohort enrolment and another 
10,538 women due to lack of information on other covariates 
examined. Hence 66,136 women were eligible for inclusion 
in our present analysis. The Regional Ethical Committee and 
the Norwegian Data Inspectorate approved the study.
Assessment of PA level
PA level at age 14 years, 30 years and at the time of cohort 
enrolment were assessed by self-report on a scale of 1 to 10. 
PA was defined in the questionnaire as follows: “By physical 
activity we mean activity both at work and outside work, at 
home, as well as training/exercise and other physical activ-
ity, such as walking, etc. Please mark the number that best 
describes your level of physical activity; 1 being very low 
and 10 being very high”. The PA scale used for this study 
refers to the total amount of PA, including different domains, 
frequencies, durations and intensities in one global score, 
and have been recently validated. A moderate but significant 
(P , 0.001) Spearman’s rank correlation coefficient was 
found, in the range of 0.36 to 0.46, between the PA scale 
and outcomes from objective measures of a combined sensor 
monitoring heart rate and movement, and appeared valid to 
rank PA in a Norwegian population of women.
Covariates
Information collected at cohort enrolment included age; 
duration of education; height; weight; smoking history 
(including smoking status: current, former, never; duration 
and quantity of cigarettes smoked/day); alcohol consump-
tion (grams/day); detailed information on dietary habits and 
intake of certain food items which was used to calculate total 
energy intake (Kcal/day); parity; use of oral contraceptives or 
postmenopausal hormone therapy (HT); age at menarche; and 
age at menopause.16–18 History of heart failure, myocardial 
infarction, angina pectoris, diabetes mellitus, fibromyalgia, 
rheumatism and hypertension were self-reported. Information 
on cancer diagnosis before cohort enrolment was obtained 
through linkages to the database of the Cancer Registry of 
Norway.
Follow-up
Person-years were calculated from the start of follow-up 
until the date of emigration, death, or end of the study 
period (December 31st 2008), whichever occurred first. 
We obtained information on date of emigration and death 
from the National Population Register. Cause of death was 
obtained from the National Register for Causes of Death, 
and categorized into specific causes of death: CVD deaths 
(ICD-10: I00-I99), including stroke, coronary heart disease, 
and other vascular causes; cancer deaths (ICD-10: C00-D48) 
and other-cause deaths (from causes other than CVD and 
cancer). The combination of the aforementioned categories 
was classified as all-cause mortality.
statistical analysis
Characteristics of the study population are presented as means 
and standard deviations, and frequency tabulations over the 
different PA levels. Cox proportional hazards regression, 
with follow-up time as the time scale, was used to calculate 
adjusted hazard ratios (HRs) (interpreted as estimates of 
RRs) and corresponding 95% confidence intervals (CIs), 
which were used to examine the association between PA level 
and all-cause, CVD and cancer mortality. The proportional 
hazard assumption was checked using Schoenfeld residuals 
and Kaplan–Meier plots, which suggested no evidence of 
deviation from proportionality. The initial survival analyses 
were done by PA level adjusted for age and further built up 
in multivariate models, with covariates added in a backward Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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stepwise manner to take possible confounders into account. 
Additional analyses were conducted separately by age group, 
body mass index (BMI) and history of CVD, diabetes mel-
litus or prevalent cancer to determine whether associations 
were stronger in these subgroups. The analyses were repeated 
excluding women with CVD, diabetes mellitus or prevalent 
cancer to minimize the potential effect of reverse causality. PA 
level at baseline was entered into the Cox regression models 
as a categorical variable with 10 categories, in order to reflect 
the study scale. PA level 5 (moderate PA level) in the study 
scale was used as the reference category, compared to PA 
levels 1–4 (low PA levels), and 6–10 (high PA levels).
Covariates examined in the multivariate Cox regression 
models were age (40–49, 50–59, $ 60 years); BMI (weight in 
kilograms divided by height in centimeters squared, , 18.5, 
18.5–24, 25–29, $ 30) with the second category as the refer-
ence; height (cm); total energy intake (Kcal/day). Smoking 
status (never, former, current), smoking duration (years) and 
quantity smoked (pack-years = the total number of years a 
smoker smoked 20 cigarettes/day) were combined in the 
analysis as one variable (age at start $ 20 years and current 
smoker, age at start $ 20 years and former smoker, age at 
start , 20 years, 0–19 pack-years and current smoker, age at 
start , 20 years and former smoker, and finally $ 20 pack-
years, age at start , 20 years and current smoker). Duration 
of education (0–9, 10–12 and $ 13 years) and menopausal 
status at enrolment (postmenopausal yes/no) were further 
included. Baseline information on menopausal status was 
available for 50,875 women, and the remaining women 
were either perimenopausal (N = 6730), hysterectomized 
at , 53 years of age (N = 2150), HT users , 53 years of 
age (N = 5477) or had missing information (N = 1828). Use 
of HT was registered as ever or never, and self-reported 
disease (yes/no to any of the following: heart failure, myo-
cardial infarction, angina pectoris, diabetes mellitus, fibro-
myalgia, rheumatism or hypertension) was also included 
in order to analyze each disease as a separate covariate. 
Alcohol intake was divided into four categories (none, 
low = 0.1–3.9 grams/day, medium = 4.0–10.0 grams/day 
and high intake . 10.0 grams/day) with low intake as refer-
ence category, and information on age at first birth (, 20, 
20–25, . 25 years) and parity (0, 1, 2, $ 3 children) was 
combined into one variable.
PAF was interpreted as the proportional reduction in the 
average population mortality risk that would occur if low 
PA levels were eliminated from the population, assuming 
that the distribution of the adjustment variables remained 
unchanged.19 PAF was estimated using the following 
  equation: PAF = (Pe (RR - 1)/1 + Pe (RR - 1)), where Pe is 
the proportion of the exposed population, and RR is the risk 
estimate for the exposed compared to the unexposed popula-
tion in the final multivariate proportional hazards regression 
model, including all aforementioned covariates. The cut-off 
point a priori for the exposed population was set at PA level 4 
or less, which divided the study population in two: exposed 
(PA levels 1–4) and unexposed (PA levels 5–10). Analyses 
were conducted using STATA version 11.0, special edition 
(StataCorp, Lakeway Drive, College Station, TX).
Results
Characteristics of the study population at cohort enrol-
ment and mortality during follow-up are given in Table 1. 
During 705,980 person-years of follow-up from 1996 to 
December 31st 2008, 2572 deaths were reported. The mean 
age of the participants at baseline was 50.5 years (standard 
deviation, 41–70 years) (Table 1).
Self-reported PA level and health-related characteristics 
of study women are shown in Table 2 by PA level. Almost 
30% of the women reported low PA levels (levels 1–4), and 
women who reported moderate to high PA levels (levels 5–10) 
tended to be leaner and had a higher total energy intake. 
Women with a PA level of 1 were more often current smokers 
compared to women with moderate to high PA levels. CVD 
was reported by 13% of study women, and this proportion 
was lower among women reporting moderate to high PA 
levels compared with those who reported low PA levels. 
A similar pattern was observed for diabetes mellitus, which 
was reported by 1.5% of study women. A total of 4.2% of 
women were diagnosed with cancer before cohort enrolment, 
and there was a higher percentage of prevalent cancer among 
women with a PA level of 1 (Table 2).
Survival analysis of all-cause mortality with adjustments 
for different covariates showed a significantly increased 
Table 1 Characteristics of the study population at baseline and 
mortality during follow-up – The norwegian Women and Cancer 
study
Characteristics
number of women 66,136
Mean age at entry (sD), years 50.5 (6.55)
Mean person-years of follow-up (sD) 10.70 (1.48)
Total person-years at risk 705,980
number of deaths in the follow-up period 2572
number of deaths by cause
  CVD 401
  Cancer 1584
  Other causes 587
Abbreviations: sD, standard deviation; CVD, cardiovascular disease.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Table 2 Physical activity (PA) level and health-related characteristics according to PA level at cohort enrolment in 1996–1998 among 
66,136 women from the norwegian Women and Cancer study
Characteristics PA level
1 2 3 4 5 6 7 8 9 10
n 949 2421 5810 9713 16,862 12,021 9828 5489 1896 1147
PA level, % 1.43 3.7 8.8 14.7 25.5 18.2 14.9 8.3 2.9 1.73
Age, mean (years) 53.6 52 51.3 50.9 50.5 50 49.8 50 50.5 51.4
Duration of education, mean (years) 10.4 11.3 11.8 12 11.9 12 12.3 11.9 11.5 10.8
BMi, mean (kg/m2) 26.6 26.5 25.8 25.3 24.6 24.1 23.7 23.5 23.4 23.5
height, mean (cm) 165.1 165.9 165.9 166 166.2 166.3 166.4 166.1 166.2 165.6
Weight, mean (kg) 72.7 72.9 71.1 69.7 68 66.7 65.7 65 64.7 64.6
Current smoker (%) 44.9 39.4 34.5 32.5 32.3 30 28.6 30.9 32.3 36.7
Alcohol consumption (grams/day) 3.0 2.9 3.4 3.3 3.2 3.3 3.4 3.2 3.0 2.6
Total energy intake, mean (Kcal/day) 1472 1515 1548 1592 1626 1661 1686 1713 1738 1758
nulliparous (%) 9.5 10.0 9.5 9.0 8.1 7.7 7.8 9.1 7.5 8.4
First birth, mean age (years)a 23.5 24 23.9 23.9 24 24 23.8 23.5 23.3 23.9
hormone therapy use at enrolment (%) 36.8 35.6 33.8 32.5 32.1 30.1 29.3 27.9 29.6 26.7
Postmenopausal at enrolment (%)b 74.7 65.2 58.8 56.5 54.0 49.5 48.4 50.5 53.0 57.8
Cardiovascular disease (%)c 27.8 23.3 18.7 16.4 13.2 11.3 10.4 10.3 9.3 11.2
Diabetes mellitus (%) 4.6 3.7 2.3 1.5 1.5 1.3 0.9 1.0 1.2 2.3
Cancer (%)d 7.1 6.0 5.2 4.4 4.4 3.7 3.6 3.4 3.6 4.5
Notes: aAmong those who had children; bPostmenopausal status based on 50,875 women, excluded from this category were 6291 women classified as perimenopausal, 2150 
with hysterectomy , 53 years of age and 5477 hormone therapy users , 53 years of age; cSelf-reported cardiovascular diseases defined as heart failure, myocardial infarction, 
angina pectoris, and hypertension; dinformation on cancer diagnosis before cohort enrolment obtained from the Cancer registry of norway.
risk of mortality for women with low PA levels (level 1 
RR = 2.35; 95% CI: 1.94–2.84, level 2 RR = 1.71; 95% CI: 
1.45–2.00, level 3 RR = 1.30; 95% CI: 1.14–1.49, level 4 
RR = 1.07; 95% CI: 0.95–1.22), compared with women with 
a moderate PA level (Table 3). The association between PA 
level and all-cause mortality showed a significant overall 
trend (P , 0.001) of reduced mortality risk in women with 
moderate to high PA levels compared to women with low PA 
levels. However, the shape of the association seemed non-
linear; more like an L-shape, indicating no additive effect on 
mortality beyond the moderate PA level (Figure 1).
CVD mortality risk for women with a PA level of 1 was 
found to be 3.5 times higher (95% CI: 2.41–5.10) than for 
women with a moderate PA level (Table 3). PA levels of 2, 
3 and 4 separately showed an increased risk as well (though 
not significant), albeit not as high as for PA level 1 (Table 3). 
The overall trend for CVD mortality risk in women with low 
PA levels was significant (P , 0.001). The results indicated 
a significant trend (P = 0.002) of increased risk of cancer 
mortality for women with decreasing PA levels. Separate 
results for PA levels 1, 2 and 3 were RR = 1.32 (95% CI: 
0.96–1.81), 1.48 (95% CI: 1.19–1.84) and 1.26 (95% CI: 
1.06–1.50), respectively.
Participants with self-reported diseases or prevalent 
  cancer at baseline were included and adjusted for in the 
main analytical model. The results of sensitivity analyses 
after exclusion of all women with CVD, diabetes mellitus, or 
prevalent cancer, did not significantly change the results (data 
not shown) and these participants were therefore retained in 
the final analysis. Survival analysis was conducted in strata of 
age, BMI and history of CVD, diabetes mellitus and cancer. 
No evidence of a differential effect of PA level on mortality 
according to age, BMI, or history of included disease was 
found, indicating that the increased mortality risk found in 
the main survival analyses are independent of these factors 
(data not shown).
The proportion of the population with low PA levels 
was 29% with an adjusted RR of 1.45 (95% CI: 1.34–1.57) 
for all-cause mortality, 1.44 (95% CI: 1.17–1.76) for CVD 
mortality and 1.29 (95% CI: 1.16–1.43) for cancer mortality 
for the exposed compared to the unexposed population. Our 
results showed that 11.5% of all-cause mortality, 11.3% of 
CVD mortality and 7.8% of cancer mortality was attributable 
to low PA levels.
Discussion
We found a significant trend of reduced all-cause mortality 
with increasing PA level, although the shape of the inverse 
association was non-linear and more L-shaped, with no 
additional effect beyond the moderate PA level of 5. Women 
reporting low PA levels (ie, PA levels 1–4) had a signifi-
cantly increased risk of all-cause mortality, with a stronger 
association for CVD than for cancer-related   mortality. 
Separate subgroup analyses indicated that the findings were Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Table 3 Relative risks (RRs) and 95% confidence intervals (CIs) 
of the association between physical activity (PA) level and all-
cause, cardiovascular disease and cancer mortality among 66,136 
women from the norwegian Women and Cancer study
PA levela N of  
deaths
Age-adjusted Multivariate
RR (95% CI) RR (95% CI)
All-cause mortality
1 139 3.17 (2.64–3.82) 2.35 (1.94–2.84)
2 203 2.04 (1.74–2.39) 1.71 (1.45–2.00)
3 321 1.40 (1.22–1.60) 1.30 (1.14–1.49)
4 402 1.09 (0.96–1.23) 1.07 (0.95–1.22)
5 621 1.0 1.0
6 342 0.80 (0.70–0.93) 0.83 (0.73–0.95)
7 276 0.81 (0.70–0.93) 0.86 (0.75–0.99)
8 170 0.87 (0.74–1.03) 0.89 (0.75–1.06)
9 54 0.76 (0.58–1.00) 0.76 (0.58–1.01)
10 44 0.94 (0.69–1.28) 0.86 (0.63–1.17)
P for trend ,0.001 ,0.001
Cardiovascular disease mortality
1 44 6.04 (4.21–8.66) 3.50 (2.41–5.10)
2 32 2.10 (1.37–3.08) 1.50 (0.99–2.25)
3 46 1.31 (0.92–1.86) 1.12 (0.79–1.60)
4 60 1.10 (0.78–1.49) 1.00 (0.72–1.39)
5 92 1.0 1.0
6 48 0.77 (0.5–1.09) 0.83 (0.58–1.17)
7 40 0.80 (0.55–1.17) 0.89 (0.61–1.30)
8 29 1.01 (0.67–1.55) 1.07 (0.71–1.63)
9 5 0.47 (0.19–1.15) 0.47 (0.19–1.15)
10 5 0.70 (0.28–1.71) 0.62 (0.25–1.53)
P for trend ,0.001 ,0.001
Cancer mortality
1 43 1.60 (1.17–2.19) 1.32 (0.96–1.81)
2 105 1.67 (1.35–2.08) 1.48 (1.19–1.84)
3 192 1.32 (1.11–1.57) 1.26 (1.06–1.50)
4 252 1.07 (0.91–1.25) 1.07 (0.91–1.25)
5 399 1.0 1.0
6 234 0.85 (0.73–1.00) 0.88 (0.75–1.03)
7 188 0.85 (0.72–1.01) 0.90 (0.76–1.07)
8 111 0.88 (0.72–1.09) 0.92 (0.74–1.13)
9 37 0.82 (0.58–1.14) 0.84 (0.60–1.17)
10 23 0.78 (0.51–1.18) 0.75 (0.49–1.15)
P for trend ,0.001 ,0.002
Notes: Data are adjusted in the multivariate model for age at cohort enrolment, body 
mass index, height, smoking status, years of smoking, amount of smoking, alcohol 
intake, menopausal status, age at first birth, parity, hormone therapy use, cardiovascular 
disease diabetes mellitus and prevalent cancer. reference level for body mass index is 
normal weight and for alcohol intake the reference category is low intake. Duration of 
education in years and total energy intake was tested in the model, but not included 
in the final analytical model as they did not change the risk estimates. aAll levels of PA 
from the study scale, 1 being the lowest PA level, and 10 being the highest.
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Figure 1 Multivariate relative risks (rrs) of all cause, CVD and cancer mortality and 
physical activity (PA) level.
Abbreviation: CVD, cardiovascular disease.
  independent of age, BMI and history of CVD, diabetes 
mellitus, or cancer. PAF calculation showed that 11.5% of 
all-cause deaths, 11.3% of CVD deaths and 7.8% of cancer 
deaths were attributable to low PA levels.
Strengths of our study include the prospective design, 
the large sample size, relatively high response rates, almost 
complete follow-up (99.9%) with almost 11 years of mean 
follow-up time, and the evaluation of cause-specific   mortality. 
The study information on HT use20 and dietary habits21,22 are 
considered valid. The NOWAC cohort is representative of 
the Norwegian female population in the studied age groups, 
and there was no major selection bias that would invalidate 
a PAF calculation.15
Despite the different methods that exist to measure PA 
level, a substantial amount of evidence from observational 
studies confirms an inverse relationship between low PA 
levels and increased mortality risk in women.2,12,23,24 Our 
findings are in line with these observations for all-cause, 
CVD and cancer mortality. Our observations suggested that 
the relationship is non-linear, with the greatest benefit to be 
had by changing from a PA level of 1 to any level between 2 
and 5, which has also been confirmed in other studies.23
Physical inactivity is considered the fourth leading cause 
of death worldwide.25 In our study, assuming causality, 
the PAF for low PA levels among women was 11.5% for 
all-cause, 11.3% for CVD and 7.8% for cancer mortality, 
which is substantial. For modifiable factors like PA level, 
PAF is useful for the planning of public health strategies 
and interventions. The Nurses’ Health study in the United 
States found a PAF of 17% for all-cause, 28% for CVD and 
9% for cancer mortality among women reporting a duration 
of PA of less than 30 minutes per day.26 In a global health 
report25 the estimated PAF of mortality was 8% for physical 
inactivity in high-income countries. However, underestima-
tion is likely as PA level measures were limited.25 Our results 
indicated a significant, but weaker trend in the association 
between PA and cancer mortality than CVD mortality. Cancer 
develops over several years before symptoms appear and are 
  diagnosed. This suggests that duration of follow-up is critical 
and must be of a certain length to capture the magnitude 
of an   association. Among environmental risk factors for 
cancer incidence, lifestyle factors such as tobacco use, poor 
nutrition, obesity and physical inactivity, which we adjusted Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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for in our study, account for about one-third of all cancers.27 
We further adjusted for hormone use (oral contraceptives and 
HT) and reproductive factors. Furthermore, our findings are 
in line with several other studies that suggested an association 
between reduced cancer mortality and PA level.28–30
Our study has some limitations. PA level in our study 
was self-reported and assessed at baseline only. Changes 
in PA level over time could introduce bias. Therefore the 
interpretation of our results should take into consideration 
the possibility of changes in behaviour over time: if anything 
PA levels decrease with age,31 and therefore our results are 
probably underestimates of the true PAF. Measurement errors 
are inevitable and self-report is a crude measure of PA level, 
which necessarily entails some degree of   misclassification.32 
A known problem of self-reporting of a desirable behaviour 
like PA is the tendency to report levels that are higher than 
one really has.33 However, the size of the NOWAC cohort 
limits the use of other more accurate measures such as 
accelerometer or heart rate monitors. The results from our 
validation study indicated that the scale of 10 PA levels 
is sufficient to differentiate between levels of the total 
amount of PA. Although the challenge of equating different 
total amounts of PA to the different PA levels on the scale 
remains, the 10 categories represent ordered levels of the 
total amount of PA which have a strong predictive value in 
relation to   mortality. Studies have shown that a higher total 
volume of PA is clearly associated with decreased all-cause 
mortality.12,34 Total volume of PA refers to energy expenditure 
related to activity quantified by duration and frequency.27 If 
total volume of PA is the main contributor in the relationship 
between mortality and PA, it stands to reason that our global 
score, which includes frequency, intensity and duration of PA 
to deduce PA levels, is appropriate for use in the estimation 
of the magnitude of a given effect.
A weakness of our study is the reliance on self-report 
for all covariates examined. This could introduce misclas-
sification error, thereby affecting our estimates. However, 
in the NOWAC Study information on the use of HT20 and 
dietary habits, including alcohol habits,21,22 have been vali-
dated with good results. Furthermore, information on parity 
and duration of education has been compared to national 
registers with no statistically significant differences found.15 
Self-reported information on height and weight has not yet 
been validated in the NOWAC Study, but ongoing research 
(unpublished) indicates a limited extent of misclassification 
bias. Despite certain limitations, self-reporting methods are 
considered adequate to deal with large sample sizes, practical 
to administer, and less expensive.
Disease or preliminary stages of a disease may inhibit 
a person’s ability to be physically active, meaning that part 
of the observed association between PA level and mortality 
may be due to confounding or reverse causation. Restricting 
the analysis to women without a history of disease would 
have entailed exclusion of almost 12,000 women, and 
therefore we retained and adjusted for this information, in 
addition to performing a sensitivity analysis excluding them. 
The effect of PA on mortality remained consistent both in 
the sensitivity analysis and the stratified analysis according 
to CVD disease, diabetes mellitus and prevalent cancer. 
Thus, it is unlikely that our results might be due to low PA 
levels explaining prevalent disease, but more probably that 
prevalent diseases are explaining low PA levels. Residual 
confounding can never be excluded in non-randomized 
studies, however, other prospective studies support our 
findings.
Despite the limitations of this study, and the existence of 
a possible spurious component in the relationship between PA 
levels and mortality, the benefits of being physically active 
are biologically plausible. An increase from low PA levels 
up to a moderate PA level would entail an 11.5% reduction 
in all-cause mortality in women in Norway. PAF estimates 
depend on RRs and the proportion of exposure in a given 
population, which has to be considered when generalizing 
to other populations where low PA levels could differ. Our 
study design cannot determine a causal association, but our 
results indicate a significant trend of reduced mortality risk 
with increasing PA levels, which suggests such an associa-
tion. The results of the present study suggest that PA level 
is an important lifestyle behaviour to target in public health 
strategies.
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